Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19 by Izadi, Z. et al.
Original Investigation | Infectious Diseases
Association Between Tumor Necrosis Factor Inhibitors
and the Risk of Hospitalization or Death Among Patients
With Immune-Mediated Inflammatory Disease and COVID-19
Zara Izadi, MPharm, MAS; Erica J. Brenner, MD; Satveer K. Mahil, PhD; Nick Dand, PhD; Zenas Z. N. Yiu, MBChB, PhD; Mark Yates, PhD; Ryan C. Ungaro, MD, MS;
Xian Zhang, PhD; Manasi Agrawal, MD; Jean-Frederic Colombel, MD; Milena A. Gianfrancesco, MPH, PhD; Kimme L. Hyrich, MD, PhD; Anja Strangfeld, MD, PhD;
Loreto Carmona, MD, PhD; Elsa F. Mateus, PhD; Saskia Lawson-Tovey, BA; Eva Klingberg, MD, PhD; Giovanna Cuomo, MD; Marta Caprioli, MD;
Ana Rita Cruz-Machado, MD; Ana Carolina Mazeda Pereira, MD; Rebecca Hasseli, MD; Alexander Pfeil, MD; Hanns-Martin Lorenz, MD; Bimba Franziska Hoyer, MD;
Laura Trupin, MPH; Stephanie Rush, BA; Patricia Katz, PhD; Gabriela Schmajuk, MD, MS; Lindsay Jacobsohn, BA; Andrea M. Seet, MPH; Samar Al Emadi, MBBS;
Leanna Wise, MD; Emily L. Gilbert, MD, PhD; Alí Duarte-García, MD, MSc; Maria O. Valenzuela-Almada, MD; Carolina A. Isnardi, MD; Rosana Quintana, MD, MSc, PhD;
Enrique R. Soriano, MD, MSc; Tiffany Y-T. Hsu, MD, PhD; Kristin M. D’Silva, MD; Jeffrey A. Sparks, MD, MMSc; Naomi J. Patel, MD; Ricardo Machado Xavier, MD, PhD;
Claudia Diniz Lopes Marques, PhD; Adriana Maria Kakehasi, MD, PhD; René-Marc Flipo, MD, PhD; Pascal Claudepierre, MD, PhD; Alain Cantagrel, MD, PhD;
Philippe Goupille, MD, PhD; Zachary S. Wallace, MD, MSc; Suleman Bhana, MD; Wendy Costello; Rebecca Grainger, MBChB, BMedSci, PhD;
Jonathan S. Hausmann, MD; Jean W. Liew, MD, MS; Emily Sirotich, BSc; Paul Sufka, MD; Philip C. Robinson, MBChB, PhD; Pedro M. Machado, MD, PhD;
Christopher E. M. Griffiths, MD; Jonathan N. Barker, MD; Catherine H. Smith, MD; Jinoos Yazdany, MD, MPH; Michael D. Kappelman, MD, MPH;
for the Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus
Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA)
Abstract
IMPORTANCE Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally
because of their ability to ameliorate shared immune pathways across immune-mediated
inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are
receiving TNF inhibitors remains insufficiently understood.
OBJECTIVE To examine the association between the receipt of TNF inhibitor monotherapy and the
risk of COVID-19–associated hospitalization or death compared with other commonly prescribed
immunomodulatory treatment regimens among adult patients with IMIDs.
DESIGN, SETTING, AND PARTICIPANTS This cohort study was a pooled analysis of data from 3
international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory
bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported
COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and
confirmed or suspected COVID-19 using online data entry portals. Adults (age 18 years) with a
diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included.
EXPOSURES Treatment exposure categories included TNF inhibitor monotherapy (reference
treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination
with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-
mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy.
MAIN OUTCOMES AND MEASURES The main outcome was COVID-19–associated hospitalization
or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted
using multilevel multivariable logistic regression models, adjusting for demographic and clinical
characteristics and accounting for country, calendar month, and registry-level correlations.
RESULTS A total of 6077 patients from 74 countries were included in the analyses; of those, 3215
individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age
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Abstract (continued)
was 48.8 (16.5) years. The most common IMID diagnoses were rheumatoid arthritis (2146 patients
[35.3%]) and Crohn disease (1537 patients [25.3%]). A total of 1297 patients (21.3%) were
hospitalized, and 189 patients (3.1%) died. In the pooled analysis, compared with patients who
received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among
those who received a TNF inhibitor in combination with azathioprine/6-mercaptopurine therapy
(odds ratio [OR], 1.74; 95% CI, 1.17-2.58; P = .006), azathioprine/6-mercaptopurine monotherapy
(OR, 1.84; 95% CI, 1.30-2.61; P = .001), methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56;
P < .001), and Jak inhibitor monotherapy (OR, 1.82; 95% CI, 1.21-2.73; P = .004) but not among those
who received a TNF inhibitor in combination with methotrexate therapy (OR, 1.18; 95% CI, 0.85-1.63;
P = .33). Similar findings were obtained in analyses that accounted for potential reporting bias and
sensitivity analyses that excluded patients with a COVID-19 diagnosis based on symptoms alone.
CONCLUSIONS AND RELEVANCE In this cohort study, TNF inhibitor monotherapy was associated
with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed
immunomodulatory treatment regimens among individuals with IMIDs.
JAMA Network Open. 2021;4(10):e2129639. doi:10.1001/jamanetworkopen.2021.29639
Introduction
Patients with COVID-19, caused by SARS-CoV-2, can have mild symptoms or experience a severe
and/or life-threatening infection.1 Comorbidities, such as lung disease, diabetes, and obesity, increase
the risk of adverse COVID-19 outcomes.2 Any benefits of treatments for immune-mediated
inflammatory diseases (IMIDs) for COVID-19 outcomes remain a topic of interest. These treatments
impact the immune system and are associated with a higher risk of infections overall.3 This
association raises concern about impaired immune response to SARS-CoV-2 among patients
currently receiving treatment for IMIDs. However, many damaging consequences of SARS-CoV-2
infection are produced by a hyperinflammatory response.4 Therefore, treatments that target an
overactive immune response may have protective benefits against adverse COVID-19 outcomes.1,4
Tumor necrosis factor (TNF) inhibitors, a class of biologic therapies that target the
proinflammatory cytokine TNF, are first- or second-line treatments for many IMIDs. International
registries of patients with IMIDs have provided initial information regarding COVID-19 outcomes
among individuals who received TNF inhibitor therapies during the pandemic. An analysis of data
from the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel
Disease (SECURE-IBD) registry, which includes patients with inflammatory bowel disease (IBD) who
were diagnosed with COVID-19, found that prevalent use compared with no use of TNF inhibitors at
COVID-19 diagnosis was not associated with severe COVID-19 (odds ratio [OR], 0.9; 95% CI,
0.4-2.2).5 A study of data from the Global Rheumatology Alliance (GRA) physician-reported registry
of COVID-19 outcomes among people with rheumatic diseases found that prevalent use compared
with no use of TNF inhibitors at COVID-19 diagnosis was associated with lower odds of COVID-19–
associated hospitalization (OR, 0.40; 95% CI, 0.19-0.81).6 An analysis of data from the Psoriasis
Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect) also
found higher odds of hospitalization among patients treated with nonbiologic systemic therapies
compared with biologic therapies, including TNF inhibitors (OR, 2.84; 95% CI, 1.31-6.18).7 Although
studies of individual registries have provided initial information, they were often underpowered to
perform more granular analyses of commonly used medications, such as monotherapy vs
combination therapy with immunomodulatory drugs, or analyses of medications that are used less
frequently.
Pooling data across registries offers an opportunity to rapidly assess any association between
TNF inhibitor therapies and COVID-19 outcomes among individuals with IMIDs and to evaluate the
JAMA Network Open | Infectious Diseases Tumor Necrosis Factor Inhibitors and Risk of COVID-19–Associated Hospitalization or Death
JAMA Network Open. 2021;4(10):e2129639. doi:10.1001/jamanetworkopen.2021.29639 (Reprinted) October 18, 2021 2/17
Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User  on 11/05/2021
consistency of findings across studies and diseases. We pooled data from these 3 international
registries of patients with IBD, psoriasis, and rheumatic diseases to evaluate the association between
TNF inhibitor monotherapy and COVID-19–associated hospitalization or death compared with other
commonly prescribed immunomodulatory regimens among individuals with IMIDs.
Methods
Registry Designs and Approvals
Details of the design of the GRA, SECURE-IBD, and PsoProtect registries have been described
previously.7-10 In brief, clinicians and trained staff directly report COVID-19 outcomes as well as
demographic and clinical characteristics of individuals with IMIDs who have confirmed or suspected
COVID-19 using online data entry portals. Quality is assessed by registry-specific data validation
teams who remove all known or potential duplicates and address erroneous or ineligible reports. The
GRA and PsoProtect registries contain only limited data; no personal identifiers, with the exception
of COVID-19 diagnosis dates, are included. The SECURE-IBD registry follows the safe harbor
deidentification standards of the Health Insurance Portability and Accountability Act. The GRA
registry was determined to be nonhuman subjects research by the United Kingdom Health Research
Authority, the University of Manchester (United Kingdom), and the University of California, San
Francisco, and informed consent was therefore not required. For the SECURE-IBD registry, the Office
for Human Research Ethics at the University of North Carolina at Chapel Hill determined that storage
and analysis of deidentified data did not constitute human subjects research and did not require
institutional review board approval or informed consent. Voluntary ethical approval was sought by
the PsoProtect registry and granted by the Leeds Research Ethics Committee (United Kingdom), who
determined that informed consent was not required because of the use of deidentified data. This
study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline for cohort studies.
COVID-19 Diagnosis
Among patients with rheumatic disease, a COVID-19 diagnosis was based on polymerase chain
reaction (PCR), antibody serology testing, or metagenomic testing; computed tomographic scans;
laboratory assays; or symptoms alone. Among patients with IBD, a COVID-19 diagnosis was based on
PCR testing, symptoms with confirmatory antibody serology testing, or rapid antigen testing. Among
patients with psoriasis, both confirmed and suspected COVID-19 diagnoses were reported; however,
information regarding the type of diagnostic testing used was not collected.
Exposures and Outcome
To obtain sufficient statistical power, each exposure category was required to have more than 250
patients in the pooled analysis. Exposure was defined as a categorical variable that comprised the
following categories: TNF inhibitor (including adalimumab, certolizumab pegol, etanercept,
golimumab, and infliximab) monotherapy (reference category), TNF inhibitors in combination with
methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy,
methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak)
inhibitor (including tofacitinib, baricitinib, and upadacitinib) monotherapy. The outcome of interest
was hospitalization or death associated with COVID-19.
Inclusion and Exclusion Criteria
We included adults (age 18 years) with a diagnosis of inflammatory arthritis, IBD, or psoriasis who
were reported to the GRA, SECURE-IBD, or PsoProtect registries, respectively, from March 12, 2020,
to February 1, 2021. Our analysis included reconciled patients only. For the GRA registry, reconciled
patients were defined as those with at least 1 of the following recorded outcomes: death, symptoms
resolved at the time of data entry, not hospitalized more than 30 days after the initial diagnosis date,
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hospitalized and discharged, or not at risk of further interventions or death. For the SECURE-IBD and
PsoProtect registries, patients were defined as reconciled after a minimum of 7 days or 14 days,
respectively, or if sufficient time had passed to observe the disease course through the resolution of
acute illness or death.
To limit confounding from other immunomodulatory medications, we excluded patients who
received an exposure treatment regimen as well as concomitant immunomodulatory drugs, except
when sulfasalazine, mesalamine, hydroxychloroquine or chloroquine, leflunomide, oral budesonide,
or glucocorticoids were used as concomitant medications.
Statistical Analysis
We used descriptive statistics to summarize the demographic and clinical characteristics of the study
population. Continuous variables were reported as means with SDs or medians with 25th and 75th
percentiles, as appropriate. Categorical variables were reported as numbers with percentages. We
performed registry-level analyses and a pooled analysis of data across the 3 registries to estimate
independent associations between exposure categories and COVID-19 outcomes. Registry-level
effect estimates were reported for exposure categories that included 10 or more patients.
Associations were estimated using multilevel multivariable mixed-effects logistic regression analysis
and reported as odds ratios (ORs) with 95% CIs. We chose mixed-effects regression analysis for its
ability to handle missing data using maximum-likelihood estimation and to fit nested random effects
to account for multilevel clustering.11
Covariates included in all models were age, sex, current smoking, IMID activity (remission vs
active disease, as reported by the clinician), important comorbidities (cardiovascular disease
[including coronary artery disease, heart failure, and arrhythmia], diabetes, hypertension,
obstructive lung disease [including chronic obstructive pulmonary disease and asthma], interstitial
or other chronic lung disease, kidney disease [including chronic kidney insufficiency and end-stage
kidney disease], obesity [defined as body mass index 30; calculated as weight in kilograms divided
by height in meters squared], and cancer, each included as a dichotomous variable), and
prednisone-equivalent glucocorticoid dose (included as a continuous variable). For the registry-level
analyses, we included the following concomitant medications: sulfasalazine, hydroxychloroquine or
chloroquine, and leflunomide for the GRA analysis and mesalamine, sulfasalazine, and oral
budesonide for the SECURE-IBD analysis. If any of these concomitant medications were significant
confounders (P < .05) in the registry-level analyses, they were also included as covariates in the
pooled analysis; patients from registries that did not include the respective concomitant medications
were assigned to the category of individuals with nonuse of these medications. Registry-level
analyses also controlled for disease diagnosis; diagnoses in the GRA registry included rheumatoid
arthritis (reference category), psoriatic arthritis, spondyloarthritis, and other inflammatory arthritis
or more than 1 type of inflammatory arthritis, and diagnoses in the SECURE-IBD registry included
Crohn disease (reference category), ulcerative colitis, and unspecified IBD.
We fitted country-level random effects to account for within-country correlations. To account
for changes in COVID-19 treatment and health service use over time, we also fitted random effects for
the calendar month of symptom onset (PsoProtect registry) or the calendar month during which the
patient was diagnosed (GRA registry) or reported (SECURE-IBD registry). The pooled model also
included registry-level random effects accounting for within-registry correlations. The hierarchical
order of nested random effects in the pooled model was country followed by time and registry. To
improve model fit, we removed influential statistical outliers identified in continuous variables (ie,
age and glucocorticoid dose) from the analyses. As a result, 2 patients were removed who received a
daily prednisone dose greater than 70 mg.
All analyses were conducted using Stata software, version 16.0 (StataCorp). The threshold for
statistical significance was 2-sided P < .05.
Rheumatology clinics from 2 large health care systems (Mass General Brigham in Massachusetts
and Mayo Clinic in Minnesota and Florida) had processes in place to systematically report all patients
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with COVID-19 to the GRA registry. To assess the extent of potential reporting bias arising from
convenience sampling, ORs were derived after reweighting the covariate distribution of patients in
the GRA registry to those of the 2 health care systems using the inverse odds of sampling weights
technique,12 and those values were compared with the original ORs using standardized difference.13
In addition, to assess the robustness of results, a pooled sensitivity analysis was performed after
excluding patients with a COVID-19 diagnosis that was based on symptoms alone.
Results
As of February 1, 2021, 8268 patients were reported to have received an exposure treatment
regimen at COVID-19 diagnosis. Of those, 5220 patients were from the GRA registry, 2720 patients
were from the SECURE-IBD registry, and 328 patients were from the PsoProtect registry. A total of
6077 patients from 74 countries met study eligibility criteria and were included in the analyses; of
those, 3441 patients (56.6%) were from the GRA registry, 2336 patients (38.4%) were from the
SECURE-IBD registry, and 300 patients (4.9%) were from the PsoProtect registry. Of the 2191
patients excluded from the analyses, most were excluded because they had a rheumatic disease
diagnosis other than inflammatory arthritis (827 patients), were patients who were nonreconciled
(581 patients), or received concomitant medications that were listed in the exclusion criteria (551
patients) (Table 1).
The demographic and clinical characteristics of the 6077 patients included in the analysis are
shown in Table 2. Most patients were from Europe (3215 individuals [52.9%]) and North America
(2015 individuals [33.2%]), and the mean (SD) age was 48.8 (16.5) years; 3563 patients (58.6%) were
female, and 2468 patients (40.6%) were male. Race and ethnicity were not addressed in these
analyses because information on race was not recorded in the PsoProtect registry, and information
on race and ethnicity was not available for all countries in the GRA registry. The most common









Total patients using an exposure treatment
regimen as of February 1, 2021a
8268 5220 2720 328
Patients excluded 2191 1779 384 28
Reason for exclusion
Age missing or <18 y 230 0 226 4
Nonreconciledb 581 581 0 0
Noninflammatory arthritis diagnosis 827 827 NA NA
Receipt of concomitant medication listed
in exclusion criteriac
551 370 157 24
Influential statistical outliersd 2 1 1 0
Abbreviations: GRA, COVID-19 Global Rheumatology Alliance; PsoProtect, Psoriasis Patient Registry for Outcomes,
Therapy and Epidemiology of COVID-19 Infection; SECURE-IBD, Secure Epidemiology of Coronavirus Under Research
Exclusion for Inflammatory Bowel Disease.
a Exposure treatment regimens included tumor necrosis factor (TNF) inhibitor monotherapy, TNF inhibitors in
combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy,
methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase inhibitor monotherapy.
b In the GRA registry, a patient was defined as reconciled if at least 1 of the following criteria were present: deceased,
symptoms resolved at the time of data entry, not hospitalized >30 days after the initial diagnosis date, hospitalized and
discharged, or not at risk of further interventions or death. In the SECURE-IBD and PsoProtect registries, a patient was
defined as reconciled after a minimum of 7 days or 14 days, respectively, or if sufficient time had passed to observe the
disease course through resolution of acute illness or death.
c Excluded concomitant medications included any medication with the exception of sulfasalazine, mesalamine,
hydroxychloroquine or chloroquine, leflunomide, oral budesonide, or glucocorticoids.
d To improve model fit, influential statistical outliers identified in continuous variables were removed. Two patients were
removed who received a daily prednisone dose >70 mg.
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Age, mean (SD), y 48.8 (16.5) 55.0 (14.4) 39.4 (15.4) 49.9 (12.6)
Sexa
Female 3563 (58.6) 2295 (66.7) 1153 (49.4) 115 (38.3)
Male 2468 (40.6) 1144 (33.2) 1139 (48.8) 185 (61.7)
Unknown 46 (0.8) 2 (0.1) 44 (1.9) 0
Regiona
Africa 24 (0.4) 16 (0.5) 7 (0.3) 1 (0.3)
Eastern Mediterranean 191 (3.1) 120 (3.5) 68 (2.9) 3 (1.0)
Europe 3215 (52.9) 1800 (52.3) 1143 (48.9) 272 (90.7)
North America 2015 (33.2) 1066 (31.0) 942 (40.3) 7 (2.3)
South America 502 (8.3) 375 (10.9) 111 (4.8) 16 (5.3)
Southeast Asia 22 (0.4) 8 (0.2) 13 (0.6) 1 (0.3)
Western Pacific 85 (1.4) 56 (1.6) 29 (1.2) 0
Unknown 23 (0.4) 0 23 (1.0) 0
Diagnosisa
Rheumatoid arthritis only 2146 (35.3) 2146 (62.4) NA NA
Spondyloarthritis only 624 (10.3) 624 (18.1) NA NA
Psoriatic arthritis only 566 (9.3) 566 (16.4) NA NA
Other inflammatory arthritis or >1
type of inflammatory arthritis
105 (1.7) 105 (3.1) NA NA
Crohn disease 1537 (25.3) NA 1537 (65.8) NA
Unspecified inflammatory bowel
disease
37 (0.6) NA 37 (1.6) NA
Ulcerative colitis 762 (12.5) NA 762 (32.6) NA
Psoriasis 300 (4.9) NA NA 300 (100)
Disease activitya
Remission 2511 (41.3) 1067 (31.0) 1369 (58.6) 75 (25.0)
Active 2918 (48.0) 1829 (53.2) 864 (37.0) 225 (75.0)
Unknown 648 (10.7) 545 (15.8) 103 (4.4) 0
Exposure treatment regimena
TNF inhibitor monotherapy 2844 (46.8) 1183 (34.4) 1445 (61.9) 216 (72.0)
TNF inhibitor plus methotrexate 669 (11.0) 575 (16.7) 87 (3.7) 7 (2.3)
TNF inhibitor plus
azathioprine/6-mercaptopurine
334 (5.5) 7 (0.2) 327 (14.0) 0
Methotrexate monotherapy 1546 (25.4) 1438 (41.8) 31 (1.3) 77 (25.7)
Azathioprine/6-mercaptopurine
monotherapy
398 (6.5) 19 (0.6) 379 (16.2) 0
Jak inhibitor monotherapy 286 (4.7) 219 (6.4) 67 (2.9) 0
Concomitant medication
Sulfasalazine 294 (4.8) 246 (7.1) 48 (2.1) NA
Mesalamine 384 (6.3) NA 384 (16.4) NA
Oral budesonide 39 (0.6) NA 39 (1.7) NA
Leflunomide 212 (3.5) 212 (6.2) NA NA
Chloroquine or hydroxychloroquine 316 (5.2) 316 (9.2) NA NA
Daily glucocorticoida
No 114 (1.9) 2650 (77.0) 2212 (94.7) 300 (100)
Yes 5162 (84.9) 683 (19.8) 118 (5.1) 0




5 (5.0-10.0) 5 (5.0-7.5) 20.0 (5.0-36.0) NA
(continued)
JAMA Network Open | Infectious Diseases Tumor Necrosis Factor Inhibitors and Risk of COVID-19–Associated Hospitalization or Death
JAMA Network Open. 2021;4(10):e2129639. doi:10.1001/jamanetworkopen.2021.29639 (Reprinted) October 18, 2021 6/17
Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User  on 11/05/2021
disease diagnoses were rheumatoid arthritis (2146 patients [35.3%]), Crohn disease (1537 patients
[25.3%]), ulcerative colitis (762 patients [12.5%]), and spondyloarthritis (624 patients [10.3%]). The
most common comorbidities were hypertension (1360 patients [22.4%]), diabetes (541 patients
[8.9%]), obstructive lung disease (430 patients [7.1%]), and cardiovascular disease (388 patients
[6.4%]). Current smoking and obesity were substantially more prevalent among patients in the
PsoProtect registry (42 patients [14.0%] and 92 patients [30.7%], respectively) compared with
those in the GRA registry (153 patients [4.4%] and 673 patients [19.6%]) or the SECURE-IBD registry
(100 patients [4.3%] and 385 patients [16.5%]).
The receipt of TNF inhibitor monotherapy was reported in 1183 patients (34.4%) from the GRA
registry, 1445 patients (61.9%) from the SECURE-IBD registry, and 216 patients (72.0%) from the
PsoProtect registry (Table 2). Methotrexate monotherapy was the most prevalent treatment
regimen at COVID-19 diagnosis among patients from the GRA registry (1438 individuals [41.8%]). The
receipt of azathioprine/6-mercaptopurine, alone or in combination with a TNF inhibitor, was
reported in a small proportion of patients from the GRA registry (26 individuals [0.8%]) and in 0
patients from the PsoProtect registry. The receipt of Jak inhibitor monotherapy was reported in 219
patients (6.4%) from the GRA registry, 67 patients (2.9%) from the SECURE-IBD registry, and 0
patients from the PsoProtect registry. A total of 1297 patients (21.3%) were hospitalized, and 189
patients (3.1%) died (Table 2). Both hospitalizations and deaths were more common among patients
from the GRA registry (939 patients [27.3%] and 166 patients [4.8%], respectively) than the
SECURE-IBD registry (316 patients [13.5%] and 20 patients [0.9%]) or the PsoProtect registry (42
patients [14.0%] and 3 patients [1.0%]).












Never or past 4791 (78.8) 2358 (68.5) 2236 (95.7) 197 (65.7)
Current 295 (4.9) 153 (4.4) 100 (4.3) 42 (14.0)
Unknown 991 (16.3) 930 (27.0) 0 61 (20.3)
BMIa
<30 4877 (80.3) 2768 (80.4) 1951 (83.5) 158 (52.7)
≥30 1150 (18.9) 673 (19.6) 385 (16.5) 92 (30.7)
Unknown 50 (0.8) 0 0 50 (16.7)
Lung disease
Interstitial 164 (2.7) 134 (3.9) 26 (1.1) 4 (1.3)
Obstructive 430 (7.1) 317 (9.2) 99 (4.2) 14 (4.7)
Cardiovascular disease 388 (6.4) 274 (8.0) 90 (3.9) 24 (8.0)
Diabetes 541 (8.9) 401 (11.7) 80 (3.4) 57 (19.0)
Hypertension 1360 (22.4) 1088 (31.6) 193 (8.3) 79 (26.3)
Kidney disease 120 (2.0) 93 (2.7) 24 (1.0) 3 (1.0)
Cancer 117 (1.9) 91 (2.6) 18 (0.8) 8 (2.7)
Hospitalization statusa
Not hospitalized 4649 (76.5) 2396 (69.6) 1996 (85.4) 257 (85.7)
Hospitalized 1297 (21.3) 939 (27.3) 316 (13.5) 42 (14.0)
Unknown 131 (2.2) 106 (3.1) 24 (1.0) 1 (0.3)
Deatha
Alive 5845 (96.2) 3266 (94.9) 2282 (97.7) 297 (99.0)
Dead 189 (3.1) 166 (4.8) 20 (0.9) 3 (1.0)
Unknown 43 (0.7) 9 (0.3) 34 (1.5) 0
Presumptive COVID-19 diagnosisb 864 (14.2) 752 (21.9) 0 112 (37.3)
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); GRA, COVID-19 Global Rheumatology
Alliance; Jak, Janus kinase; NA, not applicable;
PsoProtect, Psoriasis Patient Registry for Outcomes,
Therapy and Epidemiology of COVID-19 Infection;
SECURE-IBD, Secure Epidemiology of Coronavirus
Under Research Exclusion for Inflammatory Bowel
Disease; TNF, tumor necrosis factor.
a Subcategories are mutually exclusive.
b Presumptive diagnosis based on symptoms alone.
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Along with the prespecified covariates, the concomitant medications sulfasalazine,
leflunomide, and oral budesonide were included in the pooled multivariable model because these
medications were significantly associated with hospitalization or death in the GRA (sulfasalazine: OR,
1.55 [95% CI, 1.03-2.35; P = .04]; leflunomide: OR, 1.97 [95% CI, 1.22-3.18; P = .005]) or the
SECURE-IBD (oral budesonide: OR, 2.71; 95% CI, 1.11-6.60; P = .03) registry-level analyses. In the
pooled analysis, compared with TNF inhibitor monotherapy, higher odds of hospitalization or death
were observed among those who received a TNF inhibitor in combination with azathioprine/6-
mercaptopurine therapy (OR, 1.74; 95% CI, 1.17-2.58; P = .006). Differences in the odds of
hospitalization or death among those who received TNF inhibitor monotherapy vs a TNF inhibitor in
combination with methotrexate therapy were not statistically significant in the registry-specific
analyses (GRA: OR, 1.20 [95% CI, 0.80-1.79; P = .38]; SECURE-IBD: OR, 1.59 [95% CI, 0.76-3.34;
P = .22]) or the pooled analysis (OR, 1.18; 95% CI, 0.85-1.63; P = .33). Compared with those who
received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among
those who received methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56; P < .001),
azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61; P = .001), and Jak
inhibitor monotherapy (OR, 1.82; 95% CI, 1.21-2.73; P = .004) in the pooled analysis.
Although ORs obtained from registry-specific analyses were generally in the same direction and
of similar extent as those obtained from the pooled analysis, we observed some notable differences
(Figure and eTable in Supplement 1). Odds ratios for methotrexate monotherapy compared with TNF
inhibitor monotherapy were larger among patients in the PsoProtect registry than patients in the
SECURE-IBD or the GRA registries. Odds ratios for azathioprine/6-marcaptopurine monotherapy
compared with TNF inhibitor monotherapy were larger among patients in the GRA registry than
patients in the SECURE-IBD registry. In addition, the receipt of Jak inhibitor monotherapy was not
associated with higher odds of hospitalization or death compared with TNF inhibitor monotherapy
(OR, 0.60; 95% CI, 0.22-1.64; P = .32) among patients in the SECURE-IBD registry.
Other factors associated with higher odds of hospitalization or death in the pooled analysis
included older age (OR per 1 year increase in age, 1.04; 95% CI, 1.04-1.05; P < .001); active IMID at
COVID-19 diagnosis (OR, 1.27; 95% CI, 1.04-1.55; P = .02); obesity (OR, 1.39; 95% CI, 1.10-1.75;
P = .005); lung disease (interstitial: OR, 1.81 [95% CI, 1.12-2.95; P = .02]; obstructive: OR, 2.34 [95%
CI, 1.69-3.24; P < .001]); cardiovascular disease (OR, 1.58; 95% CI, 1.13-2.21; P = .007); diabetes (OR,
1.54; 95% CI, 1.16-2.05; P = .003); chronic kidney disease (OR, 3.10; 95% CI, 1.70-5.66; P < .001);
concomitant use of sulfasalazine (OR, 1.62; 95% CI, 1.13-2.34; P = .009), leflunomide (OR, 1.89; 95%
CI, 1.20-2.99; P = .006), or oral budesonide (OR, 2.86; 95% CI, 1.20-6.84; P = .02); and higher daily
prednisone-equivalent glucocorticoid dose (OR per 1 mg increase in dose, 1.07; 95% CI, 1.05-1.08;
P < .001) (Table 3). Female sex was associated with a protective benefit (OR, 0.79; 95% CI,
0.66-0.96; P = .02). The intraclass correlation coefficient was 0.27 (95% CI, 0.20-0.36), suggesting
that clustering of patients within country, calendar month, and registry explained 27% of the
variation in the odds of hospitalization or death. Complete results from registry-specific analyses are
shown in the eTable in Supplement 1.
We compared GRA registry-specific results with results obtained after reweighting the covariate
distribution of the GRA population to match those of rheumatology clinics that systematically
reported all patients diagnosed with COVID-19. Standardized differences between the reweighted
and original estimates were in the acceptable range of less than 0.114 (0.035 for log OR corresponding
to TNF inhibitor in combination with methotrexate therapy compared with TNF inhibitor
monotherapy; 0.002 for log OR corresponding to methotrexate monotherapy compared with TNF
inhibitor monotherapy; 0.072 for log OR corresponding to Jak inhibitor monotherapy compared with
TNF inhibitor monotherapy), suggesting that reporting bias was minimal in the GRA registry
(Table 4).
A total of 864 patients (14.2%; 112 patients [37.3%] from the PsoProtect registry, 752 patients
[21.9%] from the GRA registry, and 0 patients from the SECURE-IBD registry) received a COVID-19
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diagnosis based on symptoms alone. Our pooled results remained consistent in a sensitivity analysis
that excluded these patients (Figure).
Discussion
This cohort study found that TNF inhibitor monotherapy was associated with a lower risk of COVID-
19–associated hospitalization or death among patients with IMIDs compared with other commonly
used treatment regimens, including methotrexate, azathioprine/6-mercaptopurine, and Jak
inhibitors. After controlling for active disease and common comorbidities, the odds of hospitalization
or death among those who received TNF inhibitor combination therapies vs TNF inhibitor
monotherapy depended on the type of additional medication used in the combination regimen.
Patients receiving TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy had
higher odds of hospitalization or death compared with those receiving TNF inhibitor monotherapy,
Figure. Adjusted Odd Ratios (ORs) of COVID-19–Associated Hospitalization or Death Among Patients Receiving Immunomodulatory Treatment Regimens
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Registry-specific and pooled analyses, with TNFi monotherapy used as the reference
category. Pooled estimates were obtained using hierarchical multivariable mixed-effects
logistic regression analysis with registry and calendar month random effects nested
within country. Pooled sensitivity analysis (n = 5213) excludes patients with a
presumptive COVID-19 diagnosis (defined as a diagnosis based on symptoms alone). All
ORs were adjusted for age, sex, current smoking, immune-mediated disease activity
(remission vs active), important comorbidities (cardiovascular disease, diabetes,
hypertension, obstructive lung disease, interstitial or other chronic lung disease, kidney
disease, obesity [body mass index 30; calculated as weight in kilograms divided by
height in meters squared], and cancer), and prednisone-equivalent glucocorticoid dose.
The pooled sensitivity analysis was also adjusted for concomitant receipt of leflunomide
and oral budesonide. The pooled analysis (N = 6077) was additionally adjusted for
concomitant receipt of sulfasalazine. The COVID-19 Global Rheumatology Alliance (GRA)
registry-level analysis included 3441 patients and was adjusted for immune-mediated
disease diagnosis and concomitant receipt of sulfasalazine, hydroxychloroquine or
chloroquine, and leflunomide medications. The Psoriasis Patient Registry for Outcomes,
Therapy and Epidemiology of COVID-19 Infection (PsoProtect) registry-level analysis
included 300 patients. The Secure Epidemiology of Coronavirus Under Research
Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry-level analysis included
2336 patients and was adjusted for immune-mediated disease diagnosis and
concomitant receipt of mesalamine, sulfasalazine, and oral budesonide medications.
AZA/6MP indicates azathioprine/6-mercaptopurine; JAKi, Janus kinase inhibitor; and
MTX, methotrexate.
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whereas individuals receiving TNF inhibitors in combination with methotrexate therapy had similar
odds of hospitalization or death compared with those receiving TNF inhibitors alone.
The lower odds of unfavorable COVID-19 outcomes among patients receiving TNF inhibitors
before SARS-CoV-2 infection has several possible explanations. Although the exact mechanism of
SARS-CoV-2–associated hyperinflammation remains uncertain, high serum TNF concentrations at
the time of COVID-19 admission have been associated with organ damage and worse COVID-19
outcomes.15 Therefore, blocking TNF could inhibit this detrimental immune response. Multiple case
series reporting favorable outcomes among patients receiving TNF inhibitor therapy support this
assertion.1,16,17 Upcoming results from clinical trials investigating the use of TNF inhibitors will enable
further evaluation of the association between TNF inhibitor therapy and COVID-19 outcomes.18,19
Other possible explanations for our findings include the consequences of non-TNF inhibitor
immunosuppressive medications for COVID-19 outcomes. Thiopurine medications are associated
with a higher risk of opportunistic viral infections.20-22 A study examining data from a large registry
of patients with IBD found that the receipt of thiopurines, including azathioprine and
6-mercaptopurine, was associated with a higher risk of serious viral infection, specifically infection
from species of the Herpesviridae.23 Although data regarding other viruses cannot be directly
extrapolated to COVID-19, this higher risk highlights the potential for an association between
thiopurine use and an increased risk of unfavorable outcomes after SARS-CoV-2 infection. Moreover,
a recent study of data from the SECURE-IBD registry reported that thiopurine monotherapy and
thiopurines in combination with TNF inhibitor therapy were associated with worse COVID-19
outcomes compared with TNF inhibitor monotherapy.24 In contrast, researchers have postulated
that methotrexate therapy may decrease the cytokine storm associated with COVID-19.25,26
Table 3. Adjusted Pooled Odds of COVID-19–Associated Hospitalization or Death Among Patients
in the 3 Registriesa
Variable OR (95% CI) P value
Exposure treatment regimenb
TNF inhibitor monotherapy 1 [Reference] NA
TNF inhibitor plus methotrexate 1.18 (0.85-1.63) .33
TNF inhibitor plus azathioprine/6-mercaptopurine 1.74 (1.17-2.58) .006
Methotrexate monotherapy 2.00 (1.57-2.56) <.001
Azathioprine/6-mercaptopurine monotherapy 1.84 (1.30-2.61) .001
Jak inhibitor monotherapy 1.82 (1.21-2.73) .004
Concomitant medication
Sulfasalazine 1.62 (1.13-2.34) .009
Leflunomide 1.89 (1.20-2.99) .006
Oral budesonide 2.86 (1.20-6.84) .02
Daily prednisone-equivalent dose per 1 mg increase 1.07 (1.05-1.08) <.001
Demographic characteristic
Female sex 0.79 (0.66-0.96) .02
Age per year 1.04 (1.04-1.05) <.001
Obesity (BMI ≥30) 1.39 (1.10-1.75) .005
Current smoking 0.77 (0.51-1.17) .21
Disease activity
Active 1.27 (1.04-1.55) .02
Comorbidities
Interstitial lung disease 1.81 (1.12-2.95) .02
Obstructive lung disease 2.34 (1.69-3.24) <.001
Cardiovascular disease 1.58 (1.13-2.21) .007
Diabetes 1.54 (1.16-2.05) .003
Hypertension 1.19 (0.95-1.50) .12
Kidney disease 3.10 (1.70-5.66) <.001
Cancer 1.16 (0.65-2.07) .61
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); Jak, Janus kinase; NA, not applicable; OR,
odds ratio; TNF, tumor necrosis factor.
a All 6077 patients from the COVID-19 Global
Rheumatology Alliance (GRA); the Psoriasis Patient
Registry for Outcomes, Therapy and Epidemiology of
COVID-19 Infection (PsoProtect); and the Secure
Epidemiology of Coronavirus Under Research
Exclusion for Inflammatory Bowel Disease (SECURE-
IBD) registries were included.
b Subcategories are mutually exclusive. Odds ratios
were obtained using hierarchical multivariable
mixed-effects logistic regression analysis with
registry and calendar month random effects nested
within country. Model was adjusted for all
variables shown.
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However, our results suggest worse outcomes associated with methotrexate monotherapy
compared with TNF inhibitor monotherapy. This association could mean that TNF inhibitor therapy
is exerting a protective benefit or that methotrexate therapy is exerting a harmful consequence.
Notably, the direction of association was the same for methotrexate used in combination with TNF
inhibitors, although the effect estimate crossed the line of no effect, which is possibly associated
with the use of lower methotrexate doses in combination therapy compared with monotherapy.27,28
The timing of treatment initiation with Jak inhibitors may be an important factor associated
with COVID-19 outcomes. The second iteration of the Adaptive COVID-19 Treatment Trial (ACTT-2)
suggested a protective effect of treatment with baricitinib in combination with remdesivir therapy
against unfavorable COVID-19 outcomes among some subgroups of patients with confirmed severe
COVID-19.29 However, population-based data from patients receiving Jak inhibitors before COVID-19
diagnosis suggest worse outcomes, which is consistent with the known association between this
class of medications and reductions in the innate immune response, producing impaired viral
clearance.30 In our comparative analyses, we found that Jak inhibitor monotherapy was associated
with higher odds of hospitalization or death than TNF inhibitor monotherapy.
Strengths and Limitations
This study has strengths. These strengths include the robust worldwide collaboration between 3
international registries, which enabled evaluation of a large geographically diverse sample of adults
with IMIDs. To our knowledge, this study is the first to pool data across registries to evaluate
COVID-19 outcomes among patients with IMIDs. Pooling data increased the power of the study,
allowed for more granular analyses of medications, and improved generalizability across IMIDs.
Notably, our analyses controlled for active disease, which is only possible through the use of registry
data because this variable is not typically available in administrative databases or electronic health
records. Furthermore, clinicians or trained staff reported directly to each registry, which likely
increased the accuracy of the information.
This study also has limitations. These limitations include the risk of reporting bias because the
registries used convenience sampling. However, the results of our sensitivity analysis suggest that
reporting bias was not a substantial concern in the GRA registry. The threshold for hospitalization and
the ways in which patients are treated for COVID-19 differs over time and across regions. Such
Table 4. Sensitivity Analysis of the Extent of Potential Reporting Bias Based on Data From the GRA Registry
Exposure treatment regimena








OR (95% CI)c P value OR (95% CI)c P value
TNF inhibitor monotherapy 1 [Reference] NA 1 [Reference] NA NA NA NA
TNF inhibitor plus methotrexate 1.20 (0.80-1.79) .38 0.96 (0.57-1.64) .89 0.035 Yes Yes
Methotrexate monotherapy 2.21 (1.59-3.08) <.001 2.20 (1.82-2.65) <.001 0.002 Yes Yes
Jak inhibitor monotherapy 2.41 (1.46-3.99) .001 1.88 (1.44-2.45) <.001 0.072 Yes Yes
Abbreviations: GRA, COVID-19 Global Rheumatology Alliance; Jak, Janus kinase; NA, not
applicable; OR, odds ratio; TNF, tumor necrosis factor.
a The number of patients receiving azathioprine/6-mecaptopurine monotherapy or TNF
inhibitors in combination with azathioprine/6-mecaptopurine therapy was too small
in the rheumatology clinics to derive estimates for these exposure treatment regimens.
b Estimates were obtained after reweighting the covariate distribution of patients in the
GRA registry to match those of rheumatology clinics from health care systems that
systematically reported all confirmed and suspected COVID-19 patients, using the
inverse odds of sampling weights technique.
c All ORs were derived using hierarchical multivariable mixed-effects logistic regression
analysis with calendar month random effects nested within country and adjusted for
the following: age, sex, current smoking, immune-mediated disease diagnosis,
immune-mediated disease activity (remission vs active), important comorbidities
(cardiovascular disease, diabetes, hypertension, obstructive lung disease, interstitial or
other chronic lung disease, kidney disease, obesity [body mass index 30; calculated
as weight in kilograms divided by height in meters squared], and cancer), and receipt of
sulfasalazine, hydroxychloroquine or chloroquine, leflunomide, and prednisone-
equivalent glucocorticoid dose.
d Standardized difference measured the extent of the difference between the original
(potentially biased) and reweighted estimates. Standardized differences were derived
from log ORs according to the methods in Franklin et al.13 Values <0.1 were considered
acceptable standardized differences.14
e Regulatory agreement indicates whether original estimates replicated the statistical
significance and direction (when estimates were statistically significant) of reweighted
estimates.
f Estimate agreement indicates whether the original estimate was within the 95% CI of
the reweighted estimates.
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differences have the potential to introduce bias if insufficiently accounted for in the analyses.
Although we attempted to account for associations in hospitalization or death owing to unmeasured
temporal and geographical factors, residual confounding may remain. Additional factors that we
were unable to account for included duration and previous lines of IMID therapy. Furthermore, the
lack of a global COVID-19 registration system limited the feasibility of including a control group.
Although the case report forms were similar, the data domains across registries were not entirely
uniform. For example, time and type of COVID-19 diagnosis, rheumatic disease activity, and certain
comorbidities were recorded slightly differently across registries. These inconsistencies were
addressed, to the extent possible, through the incorporation of registry-level random effects in
multilevel modeling and through sensitivity analyses.
Conclusions
The results of this cohort study suggest that, among patients with IMIDs, receipt of TNF inhibitor
monotherapy may be associated with a lower risk of COVID-19–associated hospitalization or death
compared with other immunomodulatory treatment regimens. These findings support the
continued use of TNF inhibitor monotherapy during the pandemic and warrant further research
investigating the association of other biologic therapies with COVID-19 outcomes. Treatment with
TNF inhibitor combination therapy was associated with a more favorable safety profile when
methotrexate rather than azathioprine/6-mercaptopurine was used, suggesting that clinicians would
benefit from weighing the risks vs benefits of deescalating treatment or changing medications when
a patient is receiving concomitant TNF inhibitors and azathioprine/6-mercaptopurine.
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